Interim report January - June 2003

Report this content

Tripep AB (publ) - Interim Report, January-June 2003 · Result after tax: -SEK 11.9 million (-SEK 32.5 m). Research and development costs: SEK 6.6 million (SEK 9.4 m). The company has no other income. EPS: -SEK 0.86 (-SEK 2.34). · Research into Tripep's new anti-HIV medication, MetaboliteX, continues. · The share buyback offer was 97.9% subscribed, entailing a transfer of around SEK 40.7 million to the shareholders. · Evaluation of the patent situation in Isconova AB was deemed to be excessively complicated and Tripep's Board of Directors has consequently decided not to implement the planned acquisition. · It was decided, after the period end, that Tripep, in partnership with researchers at the Vaccine Research Institute of San Diego (VRISD), would form a new vaccine development company in the USA. The company will be known as VLP Biotech Inc. · The National Swedish Tax Board has issued general advice guidelines with regard to the buyback of shares in Tripep. For additional information, please contact Johan Ihre, CEO Tel: +46 8 449 84 80, mobile: +46 707 33 44 25 e-mail: johan.ihre@tripep.se or Anders Vahlne, Vice President, Head of Research Tel: +46 8 58581 313, mobile: +46 709 28 05 28 e-mail: anders.vahlne@labmed.ki.se Tripep is a biotech research company that develops and commercialises candidate drugs based on patented technologies: - research and development of a potential HIV-inhibiting drug, - preclinical research focusing on the development of therapeutic and prophylactic vaccines for HIV and hepatitis C, and - the RAS® technology platform. For a description of the company's technologies, please see the company's homepage at www.tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/01/20030901BIT00310/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/09/01/20030901BIT00310/wkr0002.pdf The full report

Documents & Links